ARTICLE | Company News

After BMS deal, F-star launches second newco

November 5, 2014 2:46 AM UTC

F-star Biotechnology Ltd. (Cambridge, U.K.) launched newco F-star Beta Ltd. (Cambridge, U.K.) and granted it licenses to develop antibody fragments and bispecific antibodies against certain oncology and immuno-oncology targets. F-star Biotechnology is eligible for milestones and tiered royalties. Specific terms are undisclosed.

F-star Beta is the second asset-centric company F-star Biotechnology has created. It spun out F-star Alpha Ltd. (Cambridge, U.K.) in October 2013. F-star Biotechnology, a wholly owned subsidiary of F-star GmbH (Vienna, Austria), develops Fcab antibody fragments by modifying the constant region of antibodies. ...